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Synopsis
The mechanisms for regulating PIKfyve complex activity are currently emerging. The PIKfyve complex, consisting of
the phosphoinositide kinase PIKfyve (also known as FAB1), VAC14 and FIG4, is required for the production of phos-
phatidylinositol 3,5-bisphosphate [PI(3,5)P2]. PIKfyve function is required for homoeostasis of the endo/lysosomal
system and is crucially implicated in neuronal function and integrity, as loss of function mutations in the PIKfyve
complex lead to neurodegeneration in mouse models and human patients. Our recent work has shown that the
intracellular domain of the amyloid precursor protein (APP), a molecule central to the aetiology of Alzheimer’s disease
binds to VAC14 and enhances PIKfyve function. In the present study, we utilize this recent advance to create an easy-
to-use tool for increasing PIKfyve activity in cells. We fused APP intracellular domain (AICD) to the HIV TAT domain, a
cell-permeable peptide allowing proteins to penetrate cells. The resultant TAT–AICD fusion protein is cell permeable
and triggers an increase in PI(3,5)P2. Using the PI(3,5)P2 specific GFP-ML1Nx2 probe, we show that cell-permeable
AICD alters PI(3,5)P2 dynamics. TAT–AICD also provides partial protection from pharmacological inhibition of PIKfyve.
All three lines of evidence show that the AICD activates the PIKfyve complex in cells, a finding that is important for
our understanding of the mechanism of neurodegeneration in Alzheimer’s disease.
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INTRODUCTION
Phosphoinositides are low abundance phospholipids that are im-
portant components of eukaryotic membranes [1,2]. Their inos-
itol ring can be phosphorylated or dephosphorylated by a large
number of phosphoinositide kinases and phosphatases respect-
ively, allowing their interconversion [2]. Phosphoinositides are
known to be distributed throughout the cell in a spatially and
temporally defined manner, enabling their function as regulat-
ors of signalling hubs and membrane trafficking events and
by consequence their formation and breakdown is tightly reg-
ulated. To truly understand the cycle of creation and turnover of
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phosphoinositides, it is necessary to understand how phosphoin-
ositide kinases and phosphatases are regulated. Deregulation of
phosphoinositide metabolism has been involved in a growing
number of diseases. For example, defects in the metabolism of
the endosomal phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2]
has been shown to result in severe neurodegeneration in both mice
and humans [3–6]. PI(3,5)P2 is formed by the phosphorylation of
phosphatidylinositol 3-phosphate (PI3P) at the 5-position of the
inositol ring by the PIKfyve kinase complex that in mammals con-
sists of the kinase PIKfyve, VAC14 which functions as a scaffold
for the complex and FIG4, a 5-phosphatase that also serves as co-
activator of PIKfyve [7]. Loss of function mutations in any of the
genes encoding the PIKfyve complex result in reduced PI(3,5)P2
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levels and neurodegeneration with the formation of large vacu-
oles in the brains of the affected animals in combination with
extensive cell death [3–5]. This form of neurodegeneration leads
to the early demise of the affected animals between birth and
approximately 6 weeks. In humans, mutations in the
FIG4 and VAC14 encoding genes have been shown to lead to
rare cases of genetic disorders, such as Charcot–Marie–Tooth
syndrome type 4J (CMT4J), amyotrophic lateral sclerosis (ALS)
and Yunis–Varo´n syndrome, confirming that the PIKfyve com-
plex and formation of PI(3,5)P2 are crucial for the neuronal in-
tegrity and function in humans [4,6,8].
Studying the formation and function of PI(3,5)P2 has been
hampered by its low abundance in cells, posing a significant
challenge for its detection. This problem has been alleviated to
a certain extent by the recent establishment of GFP-ML1Nx2, a
PI(3,5)P2 specific probe that allows its detection in cells [9].
PI(3,5)P2 dependent effects have been revealed using loss-
of-function mutations or RNAi of PIKfyve complex members
[3–5,10,11]. Importantly, with the establishment of two PIKfyve
inhibitors, YM201636 and Apilimod, acute inhibition of the
PIKfyve kinase has become feasible, facilitating the analysis of
PI(3,5)P2 functions [12,13]. However, so far it has not been pos-
sible to acutely increase PI(3,5)P2 levels. This is particularly
relevant as the endogenous level of PI(3,5)P2 at steady state is
very low, so being able to boost its levels experimentally would
be useful to study the functional consequences of production of
PI(3,5)P2. So far this has not been possible as the mechanism by
which the PIKfyve complex is regulated in mammals remained
unclear. However, our recent work has shown that the amyloid
precursor protein (APP), a central molecule in Alzheimer’s dis-
ease, binds to the VAC14 scaffold of the complex and enhances
the activity of the PIKfyve complex in cells [14], providing a
specific activator of this important enzyme complex. We hy-
pothesized that fusing the APP intracellular domain (known as
AICD) to a cell-permeable peptide would allow us to generate
an activator of the PIKfyve complex that can be applied exo-
genously to cells, and following cell penetration, would result in
acute activation of PIKfyve.
The creation of cell-penetrating peptides has been enabled by
the discovery that the HIV TAT protein is transduced into cells by
a mechanism that still remains ill characterized [15,16]. Based on
this discovery, a number of cell-penetrating peptides have been
established [17]. In the present study, we utilized the HIV TAT
domain (YGRKKRRQRRR) to allow AICD to penetrate cells
and test whether this would alter PIKfyve activity. We show that
AICD fused to the TAT domain is indeed able to successfully pen-
etrate cells and that TAT–AICD leads to an increase in PI(3,5)P2.
We confirm the increased PIKfyve activity using the PI(3,5)P2
probe ML1Nx2. TAT–AICD also confers partial resistance to
pharmacological PIKfyve inhibition. All three lines of evidence
establish TAT–AICD as an easy-to-use tool for exogenous activ-
ation of PIKfyve and more generally for studying the function of
the AICD.
In light of the recent controversy concerning the suggested
regulation of the vacuolar H+ -ATPase (V-ATPase) by PI(3,5)P2
[18,19], we also analysed whether PIKfyve inhibition has an
impact on the endo/lysosomal acidification. We found that both
PIKfyve inhibitors, YM201636 and Apilimod, significantly re-
duced the number of lysotracker and LampI positive vesicles,
suggesting that PIKfyve does regulate important aspects of
endo/lysosomal acidification through a yet unclear mechanism.
MATERIALS AND METHODS
Antibodies, lysotracker and PIKfyve inhibitors
Mouse monoclonal anti-LampI (clone H4A3) antibody (sc-2001)
was obtained from Santa Cruz Biotechnology. Mouse mono-
clonal anti-maltose-binding protein (MBP) antibody (E8032) and
anti-mouse Alexa 555 secondary antibody (4409S) were pur-
chased from New England Biolabs. Lysotracker DND-99 (L-
7528) was purchased from Thermo Fisher. YM201636 was pur-
chased from Abcam (ab141370), Apilimod from US Biological
(002800).
DNA manipulations and construction of
His–MBP–TAT–AICD and His–MBP–TAT
The expression plasmid for His–MBP–TAT–AICD was based on
pET28-MBP-TEV established in [20]. The 47 amino acid en-
coding DNA fragment of AICD was PCR amplified with a TAT
domain encoded in the 5’-primer of the PCR product. This primer
introduced the TAT sequence between MBP and AICD as indic-
ated in the scheme in Figure 1(A), with a HindIII site separating
TAT from AICD. This fragment was cloned with BamHI (5’) and
XhoI (3’) into pET28-MBP-TEV to result in an in frame fusion
with MBP, termed pET28-MBP–TAT–AICD. Plasmid pET28-
MBP-TAT for expression of the His–MBP–TAT control protein
was created by HindIII digest of pET28-MBP–TAT–AICD and
filling in of the cohesive ends of the HindIII site using the Pfu
polymerase and religation, thus introducing four additional bases,
resulting in a frame shift eliminating AICD expression. The ex-
pression construct for pET28-MBP–AICD was described in [21].
Protein expression and purification
His–MBP–TAT, His–MBP–TAT–AICD and His–MBP–AICD
were expressed as described in [21]. Purified proteins (concentra-
tions ranged from 2.5 to 3.5 mg/ml) were dialysed against 25 mM
Hepes, pH 7.2, 125 mM potassium acetate, 1 mM EDTA.
Cell culture transfections
HeLa cells were grown in DMEM containing 10 % foetal calf
serum and 1x penicillin/streptomycin. HeLa cells were seeded
on to glass coverslips in a 24-well plate at a density of 100000
cells per well and incubated at 37 ◦C with 5 % CO2 overnight.
The following day, the cells were transfected with the pEGFP-
c3-ML1Nx2 plasmid using Lipofectamine 2000 according to the
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Figure 1 Construct design and purification of His–MBP–TAT, His–MBP–TAT–AICD and His–MBP–AICD
(A) Schematic representation of the fusion proteins designed in the present study. The 6xHis tag was introduced for
Ni-affinity chromatography. The MBP strongly enhances the solubility of the purified proteins. The cell-penetrating TAT motif
was introduced at the C-terminus of MBP to allow the transport of the protein inside the cell. Two negative controls were
utilized: One lacking the AICD domain, controlling for AICD independent effects, one lacking the TAT domain, precluding
its entry into the cell and controlling for potential extracellular effects. (B) Coomassie stained gel of 1 μg of the purified
proteins. Although a minor degradation product of the His–MBP–TAT–AICD protein is visible, most of the preparation
represents the full length protein, indicated by the slightly higher apparent molecular mass compared with the control
proteins His–MBP–TAT and His–MBP–TAT–AICD.
manufacturer’s protocol. Cells were utilized for experiments the
following day.
Immunostaining and fluorescence microscopy
HeLa cells were fixed for 20 min in 4 % formaldehyde (from de-
polymerized paraformaldehyde) in PBS, followed by two washes
in PBS. Cells were permeabilized using 0.1 % Triton X-100 in
PBS for 4 min followed by two washes in PBS and blocking us-
ing 2 % BSA in PBS for at least 15 min. Cells were stained by use
of a primary antibody (diluted 1/300 for anti-LampI and 1/200
for anti-MBP in PBS containing 2 % BSA, incubation for 1 h at
room temperature) followed by three washes in PBS and incub-
ation with the secondary antibody (diluted 1:500 in 2 % BSA in
PBS, incubation for 1 h, room temperature). Finally, cells were
washed thrice using PBS and mounted using Mowiol. Samples
were imaged on a Leica SP5 TCS II MP confocal microscope
with a 63× oil immersion lens.
Protein uptake assay
HeLa cells, were seeded the previous day at 100000 cells/ml in
24-well plates on coverslips. Cells were treated with 350 nM or
700 nM of either MBP-AICD, MBP-TAT or MBP-TAT–AICD
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diluted in standard growth medium (DMEM with 10 % foetal
calf serum and 1x penicillin/streptomycin) and added to cells,
followed by incubation for 60 min in a tissue culture incubator.
Cells were either fixed for 20 min using 4 % formaldehyde and
mounted using Mowiol or immunostained.
Vacuole quantification
Cells were pretreated with His–MBP–TAT, His–MBP–AICD or
His–MBP–TAT–AICD for 1 h, followed by addition of 1 μM
YM201636 for 45 min before fixation in 4 % formaldehyde in
PBS. Fixed cells were imaged using a Nikon Eclipse TS100
inverted microscope under a 40× objective. Vacuolar structures
in each cell of a sample (first five cells per image, top left to
right) were counted and used to quantify the structures per cell
for each condition. One-way ANOVA (α = 0.05) was performed
in GraphPad Prism 6.
Biochemical quantification of phosphoinositides
Cells (2 × 105/well of a six-well plate) were labelled with
50 μCi/ml myo-[3H]inositol (ARC) in 2 ml inositol-free DMEM
(MPBio), supplemented with L-glutamine and dialysed foetal
calf serum (10 %, Gibco Life Technologies) for 96 h, prior to ad-
dition of His–MBP–TAT, His–MBP–AICD or His–MBP–TAT–
AICD (700 nM) for 1 h. The reaction was quenched by the re-
moval of the medium and addition of 0.6 M HClO4. Inositol lipids
were extracted from the HClO4 pellet and prepared as previously
described [22] and analysed using a modified gradient: samples
in water were loaded on to a Partisphere (5 μm) SAX column
equipped with matching guard cartridge (HiChrom) eluted with
the following gradient to 1.0 M (NH4)H2PO4, adjusted to pH 3.8
with H3PO4 (B), at a flow rate of 1.0 ml/min: 0 min, 0 % B; 5 min,
0 % B; 91 min, 30 % B; 126 min, 100 % B. Fractions (1 ml) were
collected, mixed with 2.5 ml Proflow P + scintillant (Meridian)
and assessed for radioactivity. Peaks were ascribed by co-elution
of standards in parallel runs.
Lysotracker staining
HeLa cells were seeded at a density of 100000/ml in 24-well
plates on coverslips. The following day cells were treated with
either 0 nM, 25 nM or 250 nM Apilimod, 100 nM or 1 μM
YM201636 or 10 mM ammonium sulfate for 4 h. One micro-
molar lysotracker Red was added to cells for 5 min, followed by
fixation with 4 % formaldehyde in PBS, washed twice with PBS
and mounted using Mowiol.
Automated quantification of vesicles for analysing
GFP-ML1Nx2, lyostracker and LampI
Using the Fiji version of ImageJ maximum z-projections were
created with a black mask excluding non-quantified cells, an
image of which was exported for future reference. Each cell
underwent automated Squassh analysis using the MOSAIC suite
in ImageJ as described recently [14,23]. Object data collected
from the analysis were exported to LibreOffice Calc where a
threshold for structure size was implemented – only structures
over 1 pixel in size and over 0.15 average intensity were included
in the analysis to exclude background noise introduced by the
confocal detector. Statistical analysis was performed using one-
way ANOVA with Tukey’s post-hoc test in GraphPad Prism 6
(α=0.05).
RESULTS
First we tested whether fusion of the TAT domain to the AICD
would enable effective protein transduction into the cytoplasm of
tissue culture cells. We fused the HIV TAT domain, the first well
established cell-penetrating peptide [15,16], to the N-terminus of
AICD. As a control protein we created His–MBP–TAT, identical
in design to His–MBP–TAT–AICD but lacking AICD. This fu-
sion protein should allow us to control for any effects the other
domains (e.g. 6xHis tag, MBP, TAT) may have inside the cell. As a
second negative control, we utilized the recently established His–
MBP–AICD [21] that, lacking a cell-penetrating motif, should
be unable to enter cells (Figure 1A). All three proteins were
expressed in Escherichia coli, purified by nickel affinity chro-
matography and analysed for purity and integrity (Figure 1B).
All three proteins were successfully purified (total yield10 mg
from 0.5 L expression culture). A minor degradation product was
detected for His–MBP–TAT–AICD, presumably by proteolytic
cleavage at the C-terminus of the construct, as we utilized an
N-terminal His tag for purification. However, the vast majority
of the purified protein in the sample appeared to be full length
and thus was deemed suitable for use in our assays.
We tested whether the purified proteins were able to penetrate
HeLa cells using either 350 nM or 700 nM. The fusion proteins
were added to normal growth medium for 5 min, 15 min, 30 min
and 60 min followed by fixation, immunostaining using an anti-
MBP antibody and mounting for microscopy. Confocal imaging
revealed strong labelling of cells treated with His–MBP–TAT
and His–MBP–TAT–AICD, whereas no staining was visible in
the His–MBP–AICD control lacking a TAT motif (Figure 2A).
Three hundred and fifty nanomolars led to a very similar stain-
ing pattern as 700 nM, only slightly weaker (results not shown).
These data showed that the TAT motif is necessary for MBP de-
tection in cells, suggesting that the TAT motif indeed allowed
successful cell penetration.
Interestingly, although after 5 min of incubation the staining
patterns for His–MBP–TAT and His–MBP–TAT–AICD looked
similar, the patterns diverged over time. Particularly, after 30 min
and 60 min, the His–MBP–TAT staining remained diffuse with
the outline of cells still visible. In contrast, His–MBP–TAT–
AICD showed a vesicular staining pattern, suggesting that His–
MBP–TAT–AICD had reached a vesicular destination as we
would expect according to our previous work (Figure 2A) [14].
Our recent work has shown that AICD binds the PIKfyve
complex and stimulates the formation of PI(3,5)P2 positive ves-
icles [14]. Therefore we tested, whether His–MBP–TAT–AICD
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Figure 2 His–MBP–TAT and His–MBP–TAT–AICD successfully penetrate HeLa cells
(A) A time course of protein uptake into HeLa cells for 5–60 min in which 700 nM His–MBP–TAT, His–MBP–TAT–AICD
and His–MBP–AICD were added to the cells and incubated for the times indicated, followed by fixation, permeabilization
and immunostaining with an anti-MBP antibody and an anti-mouse Alexa 555 secondary antibody. In His–MBP–TAT and
His–MBP–TAT–AICD treated cells strong staining is visible, suggesting that the TAT domain enabled protein uptake into
the cells where it was retained. The His–MBP–AICD control protein, lacking the TAT domain failed to show any appreciable
staining, demonstrating that the TAT domain is necessary for cell penetration. His–MBP–TAT showed diffuse localization
throughout the time course whereas His–MBP–TAT–AICD strongly localized to vesicular structures, particularly so after
30 min and 60 min. The outline of example cells is shown in white to facilitate the interpretation of the images. (B) HeLa
cells transfected with the PI(3,5)P2 specific GFP-ML1Nx2 probe were incubated with 700 nM of the fusion proteins indicated
for 30 min, followed by fixation, permeabilization and immunostaining with an anti-MBP antibody. His–MBP–TAT–AICD was
found to display co-localization with the GFP-ML1Nx2 probe. (A and B) White boxes indicate the area enlarged in the inset.
Scale bars, 20 μm.
displayed any co-localization with the PI(3,5)P2 specific GFP-
ML1Nx2 probe [9]. HeLa cells were transfected with the
GFP-ML1Nx2 probe and treated for 30 min with 700 nM of
the fusion proteins, followed by immunostaining with an anti-
MBP antibody. Confocal microscopy showed that the His–MBP–
TAT–AICD protein displayed instances of co-localization with
GFP-ML1Nx2, whereas we could not detect any for the His–
MBP–TAT control protein (Figure 2B). Again, no label was de-
tected with the His–MBP–AICD control consistent with the lack
of cell penetration of this protein into cells. These data suggest
that at His–MBP–TAT–AICD can reach a PI(3,5)P2 positive tar-
get organelle.
Next, we tested whether His–MBP–TAT–AICD is able to
modify PIKfyve activity. We measured the various phosphoin-
ositide species biochemically by radiolabelling HeLa cells with
tritiated inositol, challenging them with the three fusion pro-
teins and analysing the impact on the various phosphoinos-
itides using HPLC and scintillation counting [22]. We were able
to detect PI3P, phosphatidylinositol 4-phosphate (PI4P), phos-
phatidylinositol 4,5-bisphosphate [PI(4,5)P2], phosphatidylinos-
itol 3,4-bisphosphate [PI(3,4)P2], PI(3,5)P2 and phosphatidylin-
ositol 3,4,5-trisphosphate [PI(3,4,5)P3]. The only species we
were unable to quantify was phosphatidylinositol 5-phosphate
(PI5P) as this could not be separated from the much more
abundant PI4P by HPLC and is by consequence included in
the PI4P counts. The outcome of this analysis is presented
in Table 1. Phosphoinositides were normalized to the highly
abundant plasma membrane phosphoinositide PI(4,5)P2. Two
phosphoinositides were significantly increased in the His–MBP–
TAT–AICD sample: PI(3,5)P2 and PI(3,4)P2. The significant in-
crease in PI(3,5)P2 is entirely consistent with the idea that AICD
binds the PIKfyve complex and increases its activity. What mech-
anism drives the increase in PI(3,4)P2 is currently unclear.
Next, we tested whether His–MBP–TAT–AICD has an im-
pact on PI(3,5)P2 using GFP-ML1Nx2. HeLa cells transfected
with GFP-ML1Nx2 were challenged with 700 nM of the fusion
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Table 1 Quantification of phosphoinositides in HeLa cells upon treatment with
His–MBP–TAT, His–MBP–TAT–AICD and His–MBP–TAT–AICD
Data are normalized to PI(4,5)P2 being 100 % in each individual experiment and expressed as
percentage of PI(4,5)P2 +− S.E.M, n=4–7. Significant differences are indicated by *P< 0.05,
using one-way ANOVA and Dunnett’s post-hoc test performed in GraphPad Prism 6.0. PI(3,5)P2
levels are significantly increased in His–MBP–TAT–AICD treated cells compared with those
treated with control proteins His–MBP–TAT and His–MBP–AICD or untreated control cells.
Note that we were not able to quantify the lower abundant PI5P as it could not be resolved
from the PI4P peak and is by consequence included in PI4P.
Control His–MBP–TAT His–MBP–AICD His–MBP–TAT–AICD
gPI3P 10 +− 1.2 8.8 +− 0.9 9 +− 2 12 +− 2
gPI4P 230 +− 40 250 +− 70 190 +− 100 130 +− 20
gPI(3,5)P2 1.4 +− 0.4 1.3 +− 0.4 2.2 +− 0.2 3.3 +− 0.4*
gPI(3,4)P2 7 +− 3 8 +− 4 10 +− 4 22 +− 3*
gPI(3,4,5)P3 5 +− 2 4 +− 1 7 +− 2 10 +− 1
proteins for 1 h, followed by fixation, mounting and analysis by
confocal microscopy. The GFP-ML1Nx2 staining pattern was
analysed using the image segmentation tool implemented in the
MOSAIC suite in ImageJ. This software allows the automatic
detection and characterization of vesicles in cells with minimal
manual input, enabling objective analysis of the phenotype and
precluding potential bias introduced by the observer [23].
Our recent work has shown that overexpression of APP and
AICD both led to an increase in the number of GFP-ML1Nx2
positive vesicles [14]. Therefore, we first analysed the average
number of GFP-ML1Nx2 positive vesicles per cell. Using His–
MBP–TAT–AICD, we detected a significant increase in the aver-
age number of GFP-ML1Nx2 positive vesicles (Figures 3A and
3B). Compared with overexpression of APP or AICD the effect
of His–MBP–TAT–AICD appeared to be relatively small, sug-
gesting that DNA transfection of individual cells may be more
effective at delivering an exogenous protein compared with util-
izing a cell-penetrating peptide.
We also noted that the average size of GFP-ML1Nx2 positive
vesicles was increased compared with the two negative controls
(Figure 3C). Thus, His–MBP–TAT–AICD is able to increase
both the number and size of PI(3,5)P2 positive vesicles, entirely
consistent with the idea that the AICD can modulate PIKfyve
activity.
Inhibition of PIKfyve using various means is well known to
result in the formation of vacuoles, aberrant structures that are
derived from the endosomal system [3,11,24]. If AICD is able
to stimulate PIKfyve activity then it may be able to mitigate the
effect of pharmacological PIKfyve inhibition. We tested this idea
by pretreating HeLa cells with the three fusion proteins, followed
by PIKfyve inhibition using 1 μM YM201636 for 45 min. After
fixation, the number of vacuoles in cells was counted. Treatment
of cells with His–MBP–TAT–AICD significantly reduced the av-
erage number of vacuoles per cell compared with the negative
controls His–MBP–TAT and His–MBP–AICD (Figures 3D and
3E), suggesting that application of His–MBP–TAT–AICD indeed
provided partial protection from PIKfyve inhibition.
Taken together these findings show that His–MBP–TAT–
AICD is able to activate the PIKfyve complex, confirming and
extending our previous work. These data establish His–MBP–
TAT–AICD as a user friendly tool to acutely activate the PIKfyve
complex.
Dependence of acidification of endo- and lysosomes
on PIKfyve
Recent work from the Kane lab suggested that FAB1, the yeast
orthologue of PIKfyve, is able to regulate the assembly state of
the V-ATPase [18] in yeast, a proton pump that controls acidi-
fication of yeast vacuoles, organelles equivalent to lysosomes in
metazoa. However, Ho et al. [19] found that under steady state
conditions mutation of fab1 did not seem to affect vacuolar pH.
Interestingly though, FAB1 played a role in adaptation of the
vacuolar pH in response to osmotic shock, known to strongly
stimulate PIKfyve activity [25]. These observations would sug-
gest that FAB1/PIKfyve can, at least under certain conditions,
affect vacuolar acidification although it may be dispensable for
controlling the luminal pH of vacuoles under steady state condi-
tions. The situation in mammalian cells is currently not clear. Ho
et al. found in RAW macrophages in which PIKfyve was inhibited
using either 20 nM Apilimod or 1 μM MF4 (structurally similar
to YM201636) that lysotracker staining could still be detected in
vacuolar structures; however, it was restricted to the rim of vacu-
oles. Additionally, Ho et al. [19] found that endo/lysosomal pH
appeared to be unaffected by PIKfyve inhibition using ratiometric
pH detection with FITC dextran.
As the question whether PIKfyve controls endo/lysosomal
acidification is important, we attempted to clarify whether this
depends on PIKfyve. We utilized lysotracker DND-99 to analyse
acidification of organelles and performed PIKfyve inhibition us-
ing Apilimod at 25 nM and 250 nM for 4 h. From the lysotracker
staining it was evident that small, acidic vesicles remained in the
cytoplasm of PIKfyve inhibited cells, consistent with the analysis
of Ho et al. [19]. However, there was a marked reduction in their
number. Using image segmentation, we automatically detected
and quantified the average number of lysotracker positive ves-
icles in cells and found them to be reduced by approximately
50 % with both Apilimod concentrations (Figures 4A and 4B).
We also noted a slight decrease in the average vesicle intensity us-
ing 25 nM Apilimod and a somewhat more pronounced reduction
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Figure 3 His–MBP–TAT–AICD modulates PI(3,5)P2 dynamics
(A) HeLa cells expressing the PI(3,5)P2 probe GFP-ML1Nx2 were treated with 700 nM His–MBP–TAT, His–MBP–TAT–AICD
and His–MBP–AICD for 1 h followed by fixation, mounting and confocal microscopy. Compared with the negative con-
trols (His–MBP–TAT and His–MBP–AICD), His–MBP–TAT–AICD increased the number and size of GFP-ML1Nx2 positive
vesicles. Enlargements (white boxes) are presented below the respective image. Scale bar, 20 μm. (B and C) Effect
of the three proteins on GFP-ML1Nx2 (presented in A) were quantified using the MOSAIC suite in ImageJ for automatic
detection of GFP-ML1Nx2 positive vesicles. Plotted are the average number of GFP-ML1Nx2 positive vesicles per cell
(B) and their average size (C). Data were pooled from three independent experiments, a total of 83 cells were analysed
for His–MBP–TAT, 68 cells for His–MBP–TAT–AICD and 81 cells for His–MBP–AICD. Error bars are S.E.M. (D) Inhibition
of PIKfyve using YM201636 for 45 min led to the formation of vacuoles detectable by light microscopy. It was tested
whether His–MBP–TAT, His–MBP–TAT–AICD or His–MBP–AICD could modify the sensitivity of HeLa cells to PIKfyve inhib-
ition. His–MBP–TAT–AICD reduced the appearance of vacuoles compared with the two control proteins. Arrows indicate
examples of vacuoles. Scale bar, 100 μm. (E) Quantification of the average number of vacuoles per cell upon PIKfyve
inhibition. His–MBP–TAT–AICD significantly reduced the average number of vacuoles per cell compared with the negative
controls, His–MBP–TAT and His–MBP–AICD. Note that vacuoles are not detectable in the absence of PIKfyve inhibition.
A total of 150 cells per condition were analysed collected in three independent experiments. Error bars are S.E.M. Stat-
istical analysis in (B), (C) and (E) was performed using one-way ANOVA with Tukey’s post-hoc test, α=0.05, **P0.01,
****P0.0001.
using 250 nM Apilimod (Figure 4C). It should be noted that under
both conditions there is abundant vacuole formation apparent un-
der the light microscope, particularly using the higher Apilimod
concentration (results not shown). However, we did not detect
significant lysotracker staining in these vacuoles. This seems to
be an important difference between the RAW macrophage line
and HeLa cells utilized in the present study.
The reduction in the number of lysotracker positive vesicles
upon PIKfyve inhibition could be explained either by (A) reduced
acidification of endo/lysosomes or (B) a reduction in the number
of late endosomes or lysosomes. To investigate this more closely,
we analysed the LampI-positive compartment and how it reacts
to PIKfyve inhibition using 25 nM or 250 nM Apilimod for 4 h.
Interestingly, the number of LampI positive vesicles was also
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Figure 4 Inhibition of PIKfyve using Apilimod affects the number of acidified organelles and LampI positive late endo-
somes and lysosomes
(A) Inhibition of PIKfyve using two different concentrations of Apilimod (25 nM and 250 nM) led to a strong decrease
in the number of acidified organelles labelled with lysotracker Red DND-99. (B) Quantification of the average cellular
number of lysotracker positive vesicles measured using Squassh analysis in the MOSAIC suite in ImageJ. Both 25 nM and
250 nM Apilimod significantly reduced the number of lysotracker positive vesicles. (C) Quantification of average vesicular
lysotracker intensity showed a small but significant reduction in vesicular lysotracker staining with 25 nM Apilimod and a
stronger reduction with 250 nM. (A–C) Data were pooled from three independent experiments, yielding a total of 309
cells per condition. Error bars are S.E.M. (D) Analysis of the LampI positive compartment upon inhibition of the PIKfyve
complex using 25 nM and 250 nM Apilimod. Both concentrations of Apilimod reduced the number of LampI positive
vesicles. (E) Quantification of the average number of LampI positive vesicles per cell and its dependence on PIKfyve
showed that its inhibition reduced the number of LampI positive late endosomes and lysosomes. (F) Analysis of average
size of LampI positive late endosomes/lysosomes showed that although the number of LampI vesicles per cell was
reduced, their size increased, suggesting swelling or aggregation of the compartment. Data presented in (E) and (F)
were pooled from three independent experiments with 240 cells analysed per condition. Error bars are S.E.M. Statistical
analysis in (B), (C), (E) and (F) was performed using one-way ANOVA with Tukey’s post-hoc test, α=0.05, ***P0.001,
****P0.0001.
reduced by approximately 50 %, mirroring the effect seen with
lysotracker staining. We additionally noticed an increase in the
average size of LampI positive vesicles, suggesting that the com-
partment may either swell or aggregate, possibilities we could
not differentiate by light microscopy. It should be noted that in
HeLa cells, in our hands the rim of large vacuoles is almost never
LampI positive. In contrast, we detect small LampI positive ves-
icles in close proximity to enlarged vacuoles, whereas Li et al. [9]
showed very clear mCherry–LampI localization to the membrane
of these. Currently, it is unclear whether the difference stems from
the different cell models used (HeLa compared with COS1) or
whether from endogenous compared with overexpressed LampI.
To test whether the observed effect on acidification as analysed
by lysotracker staining is indeed PIKfyve specific, we also util-
ized YM201636 at 100 nM and 1 μM for 4 h. YM201636 also
reduced the number of lysotracker positive vesicles. The effect
was less pronounced than with Apilimod (Figures 5A and 5B),
entirely consistent with our experience with the two PIKfyve
inhibitors in which Apilimod consistently leads to a stronger
phenotype than YM201636. We also used ammonia, a weak
base that is trapped in acidic compartments and thereby reduces
the concentration of free protons, increasing the organellar pH
[26]. As expected the addition of 10 mM ammonium sulfate for
4 h strongly decreased the number of acidified vesicles in cells
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Figure 5 Effect of PIKfyve inhibition with YM201636 on acidic compartments
(A) Lysotracker staining revealed that PIKfyve inhibition using YM201636, similar to Apilimod, reduced the average number
of acidified vesicles in cells. The effect observed was weaker than with Apilimod which is consistent with the lower potency
of YM201636. Inhibition of acidification using the weak base, ammonia also reduced the number of lysotracker positive
vesicles, confirming that the lysotracker probe utilized indeed reflected acidification. (B) Quantification of the number of
lysotracker positive vesicles. Data were pooled from three independent experiments, a total of 240 cells per condition
were analysed for control and YM201636 samples, whereas 104 cells were analysed for ammonium sulfate treatment.
Error bars are S.E.M. Statistical analysis was performed using one-way ANOVA with Tukey’s post-hoc test, α=0.05,
***P0.001, ****P0.0001.
(Figures 5A and 5B), confirming that lysotracker truly labelled
acidified compartments.
Taken together these data suggest that inhibition of PIKfyve
affects the formation or maintenance of acidic compartments in
HeLa cells.
DISCUSSION
In the present study, we established His–MBP–TAT–AICD as a
convenient, cell-permeable tool for studying the function of the
AICD. Using this novel tool, we showed that His–MBP–TAT–
AICD is able to activate the PIKfyve complex in cells (1) by
measuring PI(3,5)P2 levels biochemically, (2) using a fluorescent
PI(3,5)P2 specific probe and (3) in a functional assay where His–
MBP–TAT–AICD partially suppressed the vacuole phenotype
of pharmacological PIKfyve inhibition. These data are in full
agreement with our recent work that showed that APP binds
VAC14 of the PIKfyve complex and that this binding translates
into increased PIKfyve activity [14]. This interplay is likely to be
conserved throughout the metazoan evolution, as we have shown
that the APP orthologue genetically interacts with the PIKfyve
complex in Caenorhabditis elegans [21].
In the present study, we provide a much needed tool for study-
ing APP-dependent signalling transduction mechanisms. APP
has previously been suggested to engage in cell signalling. It
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was suggested to regulate gene expression in a fashion similar to
Notch, where cleavage by β- and γ -secretase liberates the Notch
intracellular domain, allowing it to translocate to the nucleus
and control transcription [27], a mechanism still controversially
discussed in the case of APP. Using His–MBP–TAT–AICD will
facilitate the study of APP’s role in transcription regulation and
allow us to study functions driven by AICD.
The system presented here has two significant advantages over
previous, transfection-based delivery of AICD. First, we observed
virtually complete penetrance of the HeLa populations studied by
our TAT containing fusion proteins. Throughout our experiments,
we failed to detect cells that had not taken up the TAT fusion
protein. This represents a clear advantage over plasmid based
overexpression where cell penetrance can range, depending on
the quality transfection reagent, from very low to acceptable. This
advantage will improve biochemical studies of AICD function
where low penetrance may lead to ambiguous results. Second, this
system allows acute introduction of AICD which is not possible
with transfection based protein expression where usually at least
24 h pass between transfection and analysis of the phenotype,
during which transcription and translation gradually increase the
protein level.
One current limitation of the His–MBP–TAT–AICD fusion
protein is its suboptimal performance in immunofluorescence mi-
croscopy. In our hands, TAT-motif containing proteins strongly
adhere not only to cells but also to the glass surface of the cover
slip, resulting in strong background fluorescence in widefield
microscopy. This problem can be mitigated somewhat using con-
focal microscopy, however, ultimately the goal will be to elim-
inate this binding by using a different support surface for cells
other than glass or, alternatively, by coating the coverslips.
A second, more significant caveat of using the His–MBP–
TAT–AICD fusion in the study of PIKfyve function is the unex-
pected rise of PI(3,4)P2 levels. A large body of work has shown
that PIKfyve is undoubtedly a 5-kinase, by consequence there is
no reason to suspect that PIKfyve is implicated in the increase
in PI(3,4)P2, generated by the activity of phosphatidylinositide
4-kinases (PI4Ks). Whether APP can activate PI4Ks directly or
indirectly via its intracellular domain will need to be explored
in future work. It will be interesting to see whether this activ-
ity can be narrowed down to a specific motif in AICD and thus
potentially separated from the effect on PI(3,5)P2 via PIKfyve.
Development of exogenous activators of the PIKfyve complex
is important not only as a research tool but for the treatment of hu-
man diseases. It is extremely well documented that dysfunction of
the PIKfyve complex can lead to serious neurodegenerative dis-
eases, including CMT4J, ALS and the more recently described
Yunis–Varo´n syndrome [3,6,8]. Loss of function mutations in
a downstream effector of PIKfyve, the TRP channel TRPML-
1 (also known as mucolipin-1) leads to mucolipidosis type IV,
entailing developmental delays, psychomotor abnormalities, in-
tellectual disability and a shortened lifespan [28]. Taken together
these genetic diseases highlight the significance of the PIKfyve
pathway for neuronal function and integrity.
Our work has shown that the central molecule in Alzheimer’s
disease, APP, binds to and activates the PIKfyve complex [14].
A significant body of literature has established that APP is aber-
rantly processed in Alzheimer’s disease. This led us to propose
that aberrant cleavage of APP is likely to affect PIKfyve activity
which could result in neurodegeneration in Alzheimer’s disease
driven by reduced levels of PI(3,5)P2 [14,21,29]. If this model is
correct then exogenous activation of the PIKfyve complex should
mitigate or stop neurodegeneration in Alzheimer’s disease. Thus,
an exogenous activator of the PIKfyve complex, expected to be
beneficial in PIKfyve associated genetic diseases, may also
be effective in Alzheimer’s disease. The development of His–
MBP–TAT–AICD demonstrates that exogenous activation of
PIKfyve is feasible at least in principle. It raises the pos-
sibility that a similar function could be achieved using a
small molecule activator for PIKfyve that is more clinically
suited.
Although the number of PIKfyve effectors is slowly growing,
there is still a dearth of information on the pathways that are regu-
lated by PI(3,5)P2. Elucidation of these pathways is necessary for
us to better understand how PIKfyve dysfunction induces neuro-
degeneration and other defects in peripheral tissues such as bone.
In this light the study suggesting that the V-ATPase is regulated
by FAB1/PIKfyve is interesting [18], as the V-ATPase is import-
ant for the function of the endo/lysosomal system. Whereas data
from the Kane lab suggested that FAB1 controls the assembly
state of the V-ATPase in yeast, the Botelho lab found that in fab1
mutants the vacuolar pH is unaltered at steady state. However, the
pH of fab1 mutant cells increased more rapidly in response to a
hyperosmotic shock than in wild-type controls [19]. This would
suggest that FAB1/PIKfyve controls the vacuolar pH at least
when exposed to a hyperosmotic shock which is well known to
lead to a rapid burst of PI(3,5)P2 production [25]. When studying
the macrophage RAW cell line, Ho et al. [19] did not find any
significant effect of PIKfyve inhibition on endo/lysosomal pH
analysing individual endo/lysosomes.
Using the HeLa model we found that PIKfyve inhibition, us-
ing two different inhibitors at different concentrations, resulted
in a reduction in the number of acidic structures per cell. This
would suggest that PIKfyve plays a role in maintaining acidi-
fied organelles. It is important to note that the data of Ho et al.
[19] are not directly comparable with our data in which we ana-
lysed the number of acidified organelles per cell rather than the
acidification state of individual organelles.
Although our data suggest that PIKfyve has an impact on
the number of acidified organelles, we currently cannot say by
which mechanism. It could be a direct effect as suggested
by the Kane lab in which PI(3,5)P2 produced by PIKfyve controls
the assembly state of the V-ATPase and by consequence
controls the pH of endo/lysosomes. Another option is that
PIKfyve controls the flow of membranes to the late endosome
and lysosome. This flow may regulate the number of endo- and
lysosomes in the cell. PIKfyve was suggested to control mat-
uration from early to late endosomes and to control the fission
and fusion cycle of these via TRPML-1 [30–32]. The fact that
PIKfyve inhibition reduced the number of LampI positive endo-
and lysosomes would be consistent with this idea. Regardless of
the mechanism, PIKfyve seems to have an impact on the number
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of acidified organelles in the cell and therefore on the cellular ca-
pacity to down-regulate certain biomolecules in lysosomes [14].
It will be important to analyse the impact of PIKfyve inhibition
on the endosomal system in greater detail in future work if we
are to establish which aspects of endo/lysosomal dysfunction
lead to the profound neurodegeneration observed in patients with
PIKfyve pathway deficiency.
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